New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer

British Journal of Cancer

Volumn 113, Issue 11, 2015, Pages 1607-1614

  Lu, Yunxia ^a,b   Rodríguez, Luis Alberto García ^c   Malgerud, Linnéa ^a   González Pérez, Antonio ^c   Martín Pérez, Mar ^c   Lagergren, Jesper ^a,d   Bexelius, Tomas S ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Centro Español de Investigación Farmacoepidemiológica ^*  (Spain)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

anti diabetic medications; glycated hemoglobin; pancreatic cancer; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; METFORMIN; RECOMBINANT HUMAN INSULIN; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; DIABETIC PATIENT; DRINKING BEHAVIOR; DRUG USE; FEMALE; FOLLOW UP; HEMOGLOBIN A1C BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; POPULATION; PRIORITY JOURNAL; SMOKING; BLOOD; DIABETES MELLITUS, TYPE 2; METABOLISM; PANCREATIC NEOPLASMS; RISK FACTOR; TIME FACTOR; UNITED KINGDOM;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; METFORMIN; MIDDLE AGED; PANCREATIC NEOPLASMS; RISK FACTORS; SULFONYLUREA COMPOUNDS; TIME FACTORS; UNITED KINGDOM;

EID: 84949314944     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.353     Document Type: Article

References (42)

1. Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, Klee GG, Klee EW, Smyrk TC, Bamlet W, Han JJ, Rumie Vittar NB, de Andrade M, Mukhopadhyay D, Petersen GM, Fernandez-Zapico ME, Logsdon CD, Chari ST. (2012). Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology 143(6): 1510-1517.
2. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z. (2011). Diabetes mellitus and risk of pancreatic cancer: a meta-Analysis of cohort studies. Eur J Cancer 47(13): 1928-1937.
3. Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, Neale RE, Muscat J, Anderson K, Gallinger S, Olson SH, Miller AB, Bas Bueno-de-Mesquita H, Scelo G, Janout V, Holcatova I, Lagiou P, Serraino D, Lucenteforte E, Fabianova E, Ghadirian P, Baghurst PA, Zatonski W, Foretova L, Fontham E, Bamlet WR, Holly EA, Negri E, Hassan M, Prizment A, Cotterchio M, Cleary S, Kurtz RC, Maisonneuve P, Trichopoulos D, Polesel J, Duell EJ, Boffetta P, La Vecchia C. (2014). Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol 25(10): 2065-2072.
4. Bourke A, Dattani H, Robinson M. (2004). Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 12(3): 171-177.
5. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. (2006). Increased cancerrelated mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2): 254-258.
6. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, Fairley LL, Boniol M, Zheng T, Zhang Y, Pasterk M, Smans M, Curado MP, Mullie P, Gandini S, Bota M, Bolli GB, Rosenstock J, Autier P. (2012). Diabetes and breast cancer risk: a meta-Analysis. Br J Cancer 107(9): 1608-1617.
7. Chari ST. (2014). New-onset diabetes: a clue to the early diagnosis of pancreatic cancer. JOP 15(5): 2778.
8. Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN, Hursting SD. (2015). Metformin and Rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms. Diabetes 64(5): 1632-1642.
9. El-Serag HB, Hampel H, Javadi F. (2006). The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4(3): 369-380.
10. Elena JW, Steplowski E, Yu K, Hartge P, Tobias GS, Brotzman MJ, Chanock SJ, Stolzenberg-Solomon RZ, Arslan AA, Bueno-de-Mesquita HB, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Allen NE, Amundadottir L, Bao Y, Boeing H, Boutron-Ruault MC, Buring JE, Gaziano JM, Giovannucci EL, Duell EJ, Hallmans G, Howard BV, Hunter DJ, Hutchinson A, Jacobs KB, Kooperberg C, Kraft P, Mendelsohn JB, Michaud DS, Palli D, Phillips LS, Overvad K, Patel AV, Sansbury L, Shu XO, Simon MS, Slimani N, Trichopoulos D, Visvanathan K, Virtamo J, Wolpin BM, Zeleniuch-Jacquotte A, Fuchs CS, Hoover RN, Gross M. (2013). Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 24(1): 13-25.
11. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, MOrris AD. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
12. Farmer A. (2012). Use of HbA1c in the diagnosis of diabetes. BMJ 345: e7293.
13. Flood A, Strayer L, Schairer C, Schatzkin A. (2010). Diabetes and risk of incident colorectal cancer in a prospective cohort of women. Cancer Causes Control 21(8): 1277-1284.
14. Friberg E, Orsini N, Mantzoros CS, Wolk A. (2007). Diabetes mellitus and risk of endometrial cancer: a meta-Analysis. Diabetologia 50(7): 1365-1374.
15. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. (2010). Diabetes and cancer: a consensus report. Diabetes Care 33(7): 1674-1685.
16. Gonzalez-Perez A, Schlienger RG, Rodriguez LA. (2010). Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 33(12): 2580-2585.
17. Grote VA, Rohrmann S, Nieters A, Dossus L, Tjonneland A, Halkjaer J, Overvad K, Fagherazzi G, Boutron-Ruault MC, Morois S, Teucher B, Becker S, Sluik D, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Pala V, Tumino R, Vineis P, Panico S, Rodriguez L, Duell EJ, Molina-Montes E, Dorronsoro M, Huerta JM, Ardanaz E, Jeurnink SM, Beulens JW, Peeters PH, Sund M, Ye W, Lindkvist B, Johansen D, Khaw KT, Wareham N, Allen N, Crowe F, Jenab M, Romieu I, Michaud DS, Riboli E, Romaguera D, Bueno-de-Mesquita HB, Kaaks R. (2011). Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 54(12): 3037-3046.
18. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G. Adopt Study Group, Record Steering Committee. (2010). Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53(9): 1838-1845.
19. Hsueh WA, Orloski L, Wyne K. (2010). Prediabetes: the importance of early identification and intervention. Postgrad Med 122(4): 129-143.
20. Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, Andersen M, Auvinen A, Haukka J, Furu K, de Vries F, De Bruin ML. (2013). Use of insulin and insulin analogs and risk of cancer-systematic review and meta-Analysis of observational studies. Curr Drug Saf 8(5): 338-348.
21. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. (2009). Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69(16): 6539-6545.
22. Kordes S, Pollak MN, Zwinderman AH, Matho't RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW. (2015). Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebocontrolled phase 2 trial. Lancet Oncol 16(7): 839-847.
23. Kowall B, Rathmann W, Kostev K. (2015). Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? a retrospective database analysis. Diabetes Care 38(1): 59-65.
24. Lee JY, Jeon I, Lee JM, Yoon JM, Park SM. (2013). Diabetes mellitus as an independent risk factor for lung cancer: a meta-Analysis of observational studies. Eur J Cancer 49(10): 2411-2423.
25. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. (2007). Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 16(4): 393-401.
26. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak MN, Ma J, Fuchs CS. (2007). Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16(10): 2101-2109.
27. Onitilo AA, Berg RL, Engel JM, Glurich I, Stankowski RV, Williams G, Doi SA. (2013). Increased risk of colon cancer in men in the pre-diabetes phase. PLoS One 8(8): 70426.
28. Pannala R, Basu A, Petersen GM, Chari ST. (2009). New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 10(1): 88-95.
29. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. (2008). Prevalence and clinical profile of pancreatic cancer-Associated diabetes mellitus. Gastroenterology 134(4): 981-987.
30. Rozengurt E. (2014). Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Front Physiol 5: 357.
31. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. (2013). New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10(7): 423-433.
32. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. (2013). Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-Analysis. Am J Gastroenterol 108(4): 510-519.
33. Sjoberg Bexelius T, Garcia Rodriguez LA, Lindblad M. (2009). Use of angiotensin II receptor blockers and the risk of acute pancreatitis: a nested case-control study. Pancreatology 9(6): 786-792.
34. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G, Corrao G. (2012). Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-Analysis. Oncologist 17(6): 813-822.
35. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. (2005). Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294(22): 2872-2878.
36. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. (2012). Prediabetes: a high-risk state for diabetes development. Lancet 379(9833): 2279-2290.
37. Tan XL, Bhattacharyya KK, Dutta SK, Bamlet WR, Rabe KG, Wang E, Smyrk TC, Oberg AL, Petersen GM, Mukhopadhyay D. (2015). Metformin suppresses pancreatic tumor growth with inhibition of NFkB/STAT3 inflammatory signaling. Pancreas 44(4): 636-647.
38. Walker EJ, Ko AH, Holly EA, Bracci PM. (2015). Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer 136(6): E646-E653.
39. Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, Ren ZG, Jiang GL. (2014). Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-Analysis. Diabetes Res Clin Pract 106(1): 19-26.
40. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, Pollak MN, Manson JE, Giovannucci EL, Fuchs CS. (2013). Hyperglycemia, insulin resistance, impaired pancreatic beta-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 105(14): 1027-1035.
41. Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, Huang H, DiPaola RS, Tan XL. (2015). Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing antiapoptotic proteins Mcl-1 and Bcl-2. Oncotarget 6(25): 21208-21224.
42. Yoon JM, Son KY, Eom CS, Durrance D, Park SM. (2013). Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-Analysis. World J Gastroenterol 19(6): 936-945.